title: Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma.
abstract: BACKGROUND
  Incomplete cross-resistances between paclitaxel (PTX) and docetaxel (DTX) has been demonstrated in several types of cancer. The objective of the present study was to assess the existence of cross-resistance between PTX and DTX in esophageal squamous cell carcinoma.
  
  
  METHODS
  Patients in the PTX group received PTX without DTX pretreatment, patients in the prior DTX (Pr-DTX) group received PTX after the development of resistance to DTX, and patients in the DTX group received DTX without subsequent PTX treatment.
  
  
  RESULTS
  A total of 73 patients were enrolled. The response rates to PTX in the PTX and Pr-DTX groups were 22.7 and 20.0%, respectively. The median progression-free survival times from the first day of PTX treatment in the PTX and Pr-DTX groups were 113 (95% CI 56-154) and 97 days (95% CI 36-189), respectively. The median overall survival times from the first day of DTX treatment in the Pr-DTX and DTX groups were 315 (95% CI 124-453) and 148 days (95% CI 139-177), respectively.
  
  
  CONCLUSIONS
  There is no or incomplete clinical cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Replacement of DTX with PTX is a suitable treatment option for patients with DTX-resistant esophageal squamous cell carcinoma.
authors.forename: Hiroo
authors.initials: H
authors.lastname: Imai
authors.forename: Keigo
authors.initials: K
authors.lastname: Komine
authors.forename: Shin
authors.initials: S
authors.lastname: Takahashi
authors.forename: Ken
authors.initials: K
authors.lastname: Saijo
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Okada
authors.forename: Akihiro
authors.initials: A
authors.lastname: Kobayashi
authors.forename: Akira
authors.initials: A
authors.lastname: Okita
authors.forename: Sonoko
authors.initials: S
authors.lastname: Chikamatsu
authors.forename: Yuki
authors.initials: Y
authors.lastname: Kasahara
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Takayuki
authors.initials: T
authors.lastname: Oishi
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Shirota
authors.forename: Masanobu
authors.initials: M
authors.lastname: Takahashi
authors.forename: Hideki
authors.initials: H
authors.lastname: Shimodaira
authors.forename: Chikashi
authors.initials: C
authors.lastname: Ishioka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D012189:Retrospective Studies; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel